Contribute Try STAT+ Today

In an unusual move, a Dutch health insurer has filed a lawsuit accusing AstraZeneca (AZN) of creating an unfair monopoly for its Seroquel antipsychotic with a series of unwarranted patents that raised the cost of the medicine.

In a statement posted earlier this week on its web site, the insurance company Menzis said the drug maker “abused its position” in the marketplace and consequently forced the insurer to pay more for Seroquel because lower-cost generic alternatives were precluded from becoming available. The insurer claims more than $4.7 million in damages.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.